Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marshall Fordyce
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 361
- Beta
- 0.95
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 6.92
Financials
Net Income
$-109.47MEBITDA
$-107.49MFree Cash Flow
$-100.25MEPS (diluted)
$-1.52Shares Outstanding (diluted)
71.84M+1662.3%Operating Expenses
$112.49MCash & Debt
$499.16MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-299.62M | $-4.66 |
| 2024 | $0.00 | $-152.15M | $-2.75 |
| 2023 | $0.00 | $-95.99M | $-2.25 |
| 2022 | $0.00 | $-89.06M | $-3.35 |
| 2021 | $0.00 | $-32.61M | $-2.43 |
| 2020 | $0.00 | $-53.41M | $-14.40 |
| 2019 | $0.00 | $-11.85M | $-3.46 |
Valuation
VERAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-33.33%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·4d ago·Neutral
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbarrons.com·20d ago·Negative
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
View source ↗ - Newsinvezz.com·20d ago·Positive
Why is Vera Therapeutics stock reversing its premarket gains? Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).
View source ↗ - Newsschaeffersresearch.com·20d ago·Negative
Vera Stock Slides Despite Positive Phase 3 Results Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
View source ↗ - Newsseekingalpha.com·49d ago·Positive
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-1.61 per share
Typical surprise -5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-1.52 vs $-1.58beat
- Thu, May 7$-1.69 vs $-1.33miss
- Thu, Feb 26$-1.39 vs $-1.34miss
- Wed, Nov 5$-1.26 vs $-1.20miss
- Tue, Aug 5$-1.20 vs $-0.82miss
- Tue, May 6$-0.81 vs $-0.75miss
Estimates and results for VERA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VERA officers and directors.
- Bought
- $5.5m
- Sold
- $12.3m
5 trades
33 trades
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VERA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.